Congenital Antithrombin Deficiency
Conditions
Keywords
Antithrombin, Thrombosis, Pharmacokinetics, Hereditary Antithrombin Deficiency, Congenital Antithrombin Deficiency
Brief summary
The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.
Detailed description
Patients with Congenital Antithrombin Deficiency are at increased risk of venous thrombosis and pulmonary embolism especially when undergoing certain high risk procedures. Antithrombin replacement therapy is often administered during these periods, with or without low molecular weight heparin. Prior to assessing the efficacy of KW-3357, a new recombinant human antithrombin, the present study will determine it's pharmacokinetics, safety and tolerability in subjects who have Congenital Antithrombin Deficiency but who are currently asymptomatic and not undergoing a high-risk procedure. Up to 16 evaluable subjects will be enrolled at multiple investigational sites over a period of approximately 7 months.
Interventions
DRUGKW-3357
50IU/mL, IV single dose
Sponsors
Kyowa Hakko Kirin UK, Ltd.
Kyowa Kirin Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects at least 18 years of age with congenital Antithrombin deficiency (AT activity ≤60% of normal) in a stable condition without evidence of acute thromboembolic events * Signed IEC-approved Informed Consent Form * Subjects must not have received an infusion of Antithrombin for at least 14 days before Screening * Patients of reproductive potential must agree to follow accepted birth control methods during the study
Exclusion criteria
* Subjects who are classified as morbidly obese (defined by the presence of a body mass index \>40 kg/m2) * Subjects who have participated in a study with an investigational drug within 30 days of Screening or within 5.5 times the elimination half-life of the investigational drug before Screening, whichever period is greater * Subjects with any clinically relevant medical history or current condition or physical findings, ECG, or laboratory values which could interfere with the objectives of the study or the safety of the subject * Subjects using non-steroidal anti-inflammatories, fondaparinux sodium, dabigatran or rivaroxaban or who are expected to be treated with these drugs during the study * Subjects who have concomitant nephrotic syndrome * Female subjects who are pregnant or lactating * Subjects who are taking heparin, low molecular weight heparin and/or oral anticoagulants, with the exception of vitamin K antagonists (eg, warfarin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the pharmacokinetic profile of a single dose (50 IU/kg) of KW 3357 in subjects with congenital AT deficiency | July 2011 |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety and tolerability of a single dose (50 IU/kg) of KW-3357 in subjects with congenital AT deficiency | July 2011 |
Countries
Germany, Sweden, United Kingdom
Outcome results
None listed